Mental Health technology company, Medibio
(ASX:MEB) has announced that a clinical article on the company has been accepted for publication in EC Neurology.
EC Neurology is an internationally peer-reviewed journal.
The publication highlights Medibio’s scientific success with predicting diagnoses using multinomial logistic regression analysis.
Medibio says the findings reveal a new opportunity to improve the accuracy of psychiatric diagnosis using distinct patterns of mean heart rate and heart rate variability.
Shares in Medibio
(ASX:MEB) flat at 14 cents.
